Toggle Main Menu Toggle Search

Open Access padlockePrints

Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries

Lookup NU author(s): Professor Azfar Zaman


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Aims Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registries were heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09–3.55% in-hospital (8 registries), 0.09–1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry).Conclusions Real-world evidence from European contemporary registries shows that death, ischaemic events, and bleeding rates are lower than those reported in Phase III studies of P2Y12 inhibitors. Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a lesser degree, ticagrelor, had fewer ischaemic and bleeding events at all time points than clopidogrel-treated patients. These findings are partly related to the fact that the newer agents are used in younger and less ill patients.

Publication metadata

Author(s): Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, LopezSendón J, Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J, Jukema JW

Publication type: Article

Publication status: Published

Journal: European Heart Journal - Cardiovascular Pharmacotherapy

Year: 2016

Volume: 2

Issue: 3

Pages: 152-167

Print publication date: 01/07/2016

Online publication date: 27/01/2016

Acceptance date: 16/02/2016

ISSN (print): 2055-6837

ISSN (electronic): 2055-6845

Publisher: Oxford University Press


DOI: 10.1093/ehjcvp/pvw003


Altmetrics provided by Altmetric